Abstract:ID 92269 Poster Board 517 The opioid crisis (e.g., overdose deaths) has worsened significantly during the COVID-19 pandemic, despite a decrease in the number of prescriptions for opioids. However, the number of prescriptions for and the off-label use of gabapentinoids (gabapentin and pregabalin) as alternative medications used for chronic pain is soaring with gabapentinoids increasingly detected in opioid overdose victims, raising serious concerns about the health risks of this class of drugs. The effect of gabapentinoids on mu opioid receptor (MOR)-mediated in vivo activity is not well characterized, although a study in male rats reported that gabapentinoids decrease the potency of the opioid receptor antagonist naloxone to reverse hypoventilation by the morphinan MOR agonist heroin. Male rats (n = 8) discriminating the non-morphinan MOR agonist fentanyl (0.0032 mg/kg, intraperitoneally, i.p.) from saline under a fixed-ratio 10 schedule of food reinforcement, were used to test the following hypotheses: 1) gabapentinoids do not share discriminative stimulus effects with fentanyl; 2) gabapentinoids increase the potency of fentanyl to produce discriminative stimulus effects; and 3) gabapentinoids decrease the potency of naloxone to antagonize the discriminative stimulus effect of fentanyl. Gabapentin (10-320 mg/kg, i.p.) and pregabalin (3.2-100 mg/kg, i.p.) occasioned a maximum average, respectively, of 37.8% and 46.3% fentanyl-appropriate responding, and decreased rates of responding to 6.0% and 7.4% of control. Heroin (0.032-0.1 mg/kg, i.p.) occasioned 100% fentanyl-appropriate responding whereas the stimulant drugs cocaine (0.32-10 mg/kg, i.p.) and d -methamphetamine (0.1-3.2 mg/kg, i.p.) did not increase fentanyl-appropriate responding up to doses that significantly decreased rates of responding. Acute pretreatment with gabapentin (3.2-32 mg/kg, i.p.) or pregabalin (3.2-32 mg/kg, i.p.) dose-dependently shifted the fentanyl discrimination dose-effect function up to 17-fold to the left. In contrast, naloxone (0.01-1.0 mg/kg, i.p.) dose-dependently shifted the fentanyl discrimination dose-effect function up to 95-fold to the right. Rightward shifts by naloxone (0.1 and 1.0 mg/kg, i.p.) in the fentanyl discrimination dose-effect function were attenuated dose-dependently by gabapentin (3.2-100 mg/kg, i.p.) and pregabalin (3.2-100 mg/kg, i.p.) up to 63 fold. Similar presession treatment effects of gabapentinoids were observed with heroin. These results suggest that gabapentinoids 1) produce only partial but significant fentanyl-like discriminative stimulus effects, 2) enhance the discriminative stimulus effects of the MOR agonists including the non-morphinan (phenylpiperidine) fentanyl as well as the morphinan heroin, and 3) attenuate naloxone antagonism of the discriminative stimulus effects of the MOR agonists. These results can help guide government agencies and others develop better policies for regulating gabapentinoids and treating opioid misuse and overdose. Supported by USPHS grant R01DA058018 and the Welch Foundation (Grant AQ-0039).

Effects of Fentanyl on GABAA Receptor in Rat Hippocampal Pyramidal Neurons

Fentanyl Inhibits Air Puff-Evoked Sensory Information Processing in Mouse Cerebellar Neurons Recorded in vivo

Effects of gabapentinoids in male rats discriminating fentanyl from saline

Epidural Fentanyl Decreases the Minimum Local Analgesic Concentration of Epidural Lidocaine.

Effects of Fentanyl on Myocardial Contractility and Ca++ Mobilization in Isolated Rat Ventricular Myocytes

Effects of Different Doses of Fentanyl on Brain Areas Activated by Pain: Evidence from Functional Magnetic Resonance Imaging

Effects of propofol, midazolam, etomidate and their combination with fentanyl on intracellular Ca2+ mobilization in isolated rat ventricular myocytes

The Impact of Chronic Fentanyl Administration on the Cerebral Cortex in Mice: Molecular and Histological Effects

Pharmacological profiles of fentanyl analogs at μ, δ and κ opiate receptors

Effectiveness Comparisons of G-protein Biased and Unbiased Mu Opioid Receptor Ligands in Warm Water Tail-Withdrawal and Drug Discrimination in Male and Female Rats

Application of Receptor Theory to the Design and Use of Fixed-Proportion Mu-Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys

Effects of ohmefentanyl in anesthetic dose on the levels of monoamine transmitters and their metabolites in rat brain

Fentanyl activates opposing opioid and non-opioid receptor systems that control breathing

Actions of GABAB Receptors on the Synaptic Transmission in Rat Hippocampus CAI Cells

Gabapentinoids Increase the Potency of Fentanyl and Heroin and Decrease the Potency of Naloxone to Antagonize Fentanyl and Heroin in Rats Discriminating Fentanyl

Fentanyl induces analgesic effect through miR-381-3p/TRPM7 when combined with bupivacaine in subarachnoid injection

Transcriptional signatures of fentanyl use in the mouse ventral tegmental area

Role of glycine transporter-1 in fentanyl-induced hyperalgesia

Blockade of the Human Ether A-Go-Go–Related Gene (hERG) Potassium Channel by Fentanyl

Effect of Naloxone of Different Dosage on C-Fos Expression in Hippocampus Induced by Repeated Febrile Seizures

EFFECTS OF GLUTAMATE ON SODIUM CHANNEL IN ACUTELY DISSOCIATED HIPPOCAMPAL CA1 PYRAMIDAL NEURONS OF RATS